World News: 08:11 GMT Friday 12th July 2019. [Fortune Business Insights via Globe Newswire via SPi World News]
Pune, July 12, 2019 (GLOBE NEWSWIRE) -- The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market has been boosted by recent FDA approval for Prolastin-C. According to a report published by Fortune Business Insights, titled “”, the market will be valued at US$ 1959.8 Mn by the end of 2025. The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the forecast period. expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.
In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in AATD patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.
Rising number of AATD cases in North America is fuelling the demand for AATD augmentation therapy in this region. This in turn has led to the growth of AATD augmentation therapy market in North America and is likely to favor growth of the market in this region through the forecast period. There have been significant improvements in AATD diagnostic techniques used in many parts of Asia Pacific. Furthermore, the emphasis on AATD by the government in Asia Pacific is likely to enable growth in the regional market in the forthcoming years. Despite North America’s dominance, Asia Pacific will emerge as the fastest growing region in the forecast period.
In September 2017, Grifols received biologics license approval for Alpha-1 Proteinase Inhibitor to add a new liquid formulation to the currently licensed Prolastin C. The inclusion of this liquid may enable the launch of an additional alternative to the existing therapy. Clinical trials and proven efficacy have favored the approval for this product. With the latest addition to its product portfolio, Grifols will increase its stronghold in the global AATD augmentation therapy market. As Grifols’ products are used by a huge percentage of the global population, its new product approval will have a direct impact on the global market. Backed by successful therapies and efficient products, Grifols has accounted for the highest share in the global market. Recent product approvals have favoured the company and accounting to this, Grifols is likely to emrge dominant in the forecast period as well.
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Globe Newswire: 08:11 GMT Friday 12th July 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.